Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincenzo Nasca

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
International Journal of Molecular Sciences|September 5, 2020
Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk StratificationVincenzo Nasca, Marta Chiaravalli, Geny Piro, et al.
Nature Reviews. Clinical Oncology|April 3, 2025
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancersMargherita Ambrosini, Paolo Manca, Vincenzo Nasca, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 19, 2025
MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenterationLuca Sorrentino, Vincenzo Nasca, Elena Daveri, et al.
Frontiers in Oncology|August 5, 2022
Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literatureVincenzo Nasca, Anna Maria Frezza, Carlo Morosi, et al.
Journal for Immunotherapy of Cancer|September 4, 2021
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancerCarmine Carbone, Geny Piro, Antonio Agostini, et al.
Cancers|November 25, 2023
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 StudiesValentina Fanotto, Daniele Rossini, Mariaelena Casagrande, et al.
JCO Precision Oncology|November 7, 2024
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted AlterationRoberto Moretto, Daniele Rossini, Sabina Murgioni, et al.
International Journal of Cancer|August 24, 2023
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trialFrancesca Ligorio, Riccardo Lobefaro, Giovanni Fucà, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2024
The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitorsFilippo Ghelardi, Giovanni Fucà, Chiara Cavalli, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
International Journal of Molecular Sciences|September 5, 2020
Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk StratificationVincenzo Nasca, Marta Chiaravalli, Geny Piro, et al.
Nature Reviews. Clinical Oncology|April 3, 2025
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancersMargherita Ambrosini, Paolo Manca, Vincenzo Nasca, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 19, 2025
MSI-H locally recurrent rectal cancer: Immune checkpoint inhibitors vs. standard chemotherapy and pelvic exenterationLuca Sorrentino, Vincenzo Nasca, Elena Daveri, et al.
Frontiers in Oncology|August 5, 2022
Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literatureVincenzo Nasca, Anna Maria Frezza, Carlo Morosi, et al.
Journal for Immunotherapy of Cancer|September 4, 2021
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancerCarmine Carbone, Geny Piro, Antonio Agostini, et al.
Cancers|November 25, 2023
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 StudiesValentina Fanotto, Daniele Rossini, Mariaelena Casagrande, et al.
JCO Precision Oncology|November 7, 2024
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted AlterationRoberto Moretto, Daniele Rossini, Sabina Murgioni, et al.
International Journal of Cancer|August 24, 2023
Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trialFrancesca Ligorio, Riccardo Lobefaro, Giovanni Fucà, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2024
The Prognostic Nutritional Index in patients with microsatellite instability-high metastatic gastric or gastroesophageal cancers receiving immune checkpoint inhibitorsFilippo Ghelardi, Giovanni Fucà, Chiara Cavalli, et al.
Pageof 3